EP1594496A4 - Novel therapeutic method and compositions for topical administration - Google Patents

Novel therapeutic method and compositions for topical administration

Info

Publication number
EP1594496A4
EP1594496A4 EP04711191A EP04711191A EP1594496A4 EP 1594496 A4 EP1594496 A4 EP 1594496A4 EP 04711191 A EP04711191 A EP 04711191A EP 04711191 A EP04711191 A EP 04711191A EP 1594496 A4 EP1594496 A4 EP 1594496A4
Authority
EP
European Patent Office
Prior art keywords
compositions
topical administration
therapeutic method
novel therapeutic
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04711191A
Other languages
German (de)
French (fr)
Other versions
EP1594496A2 (en
Inventor
Adrian F Davis
L Trottet
Tadataka Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1594496A2 publication Critical patent/EP1594496A2/en
Publication of EP1594496A4 publication Critical patent/EP1594496A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
EP04711191A 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration Withdrawn EP1594496A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0303600.1A GB0303600D0 (en) 2003-02-17 2003-02-17 Novel therapeutic method and compositions
GB0303600 2003-02-17
PCT/US2004/004393 WO2004073627A2 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Publications (2)

Publication Number Publication Date
EP1594496A2 EP1594496A2 (en) 2005-11-16
EP1594496A4 true EP1594496A4 (en) 2006-05-03

Family

ID=9953155

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04711191A Withdrawn EP1594496A4 (en) 2003-02-17 2004-02-13 Novel therapeutic method and compositions for topical administration

Country Status (4)

Country Link
EP (1) EP1594496A4 (en)
JP (1) JP2007525420A (en)
GB (1) GB0303600D0 (en)
WO (1) WO2004073627A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885491B1 (en) * 2005-05-16 2020-03-06 Nutricos Technologies TREATMENT OF KERATINIC DROUGHT WITH GLYCERIDES
FR2897534A1 (en) * 2006-02-17 2007-08-24 Galderma Res & Dev USE OF TESAGLITAZAR FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
EP2238446A4 (en) * 2008-01-03 2011-07-20 Abbott Biotech Ltd Predicting long-term efficacy of a compound in the treatment of psoriasis
SG173058A1 (en) * 2009-01-23 2011-08-29 Hoffmann La Roche Pharmaceutical composition comprising aleglitazar

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294580B1 (en) * 1996-02-28 2001-09-25 Glaxo Wellcome Inc. Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773075B1 (en) * 1997-12-31 2000-05-05 Cird Galderma USE OF PPAR-GAMMA ACTIVATORS IN DERMATOLOGY
AU2001288271A1 (en) * 2000-08-17 2002-02-25 Harrihar A. Pershadsingh Methods for treating inflammatory diseases
US6573287B2 (en) * 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
WO2003003971A2 (en) * 2001-06-20 2003-01-16 Merck Sante Use of antidiabetics for making a medicine with cicatrizing effect

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294580B1 (en) * 1996-02-28 2001-09-25 Glaxo Wellcome Inc. Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

Also Published As

Publication number Publication date
EP1594496A2 (en) 2005-11-16
WO2004073627A3 (en) 2004-11-18
WO2004073627A2 (en) 2004-09-02
GB0303600D0 (en) 2003-03-19
JP2007525420A (en) 2007-09-06

Similar Documents

Publication Publication Date Title
TWI345979B (en) Topical pharmaceutical compositions for the treatment of dermatitis
IL165279A0 (en) Novel methods and compositions for alleviating pain
EP1513825A4 (en) Anti tubercular drug: compositions and methods
AU2002951833A0 (en) Compositions and therapeutic methods invloving platinum complexes
EP1603543A4 (en) Therapeutic compositions
EP1594959A4 (en) Novel therapeutic method and compositions for topical administration
EP1648364A4 (en) Pharmaceutical compositions for topical application
EP1648474A4 (en) Methods and pharmaceutical compositions for healing wounds
ZA200600025B (en) Methods and compositions for interferon therapy
EP1608385A4 (en) Therapeutic compositions
IL173148A0 (en) Methods and pharmaceutical compositions for healing wounds
HK1093896A1 (en) Medicinal composition
GB2392618B (en) Compositions for therapeutic use
GB0229258D0 (en) Medicinal compositions
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
GB0222945D0 (en) Therapeutic compositions
AU2003282722A8 (en) Therapeutic compositions
EP1600445A4 (en) Medicinal composition
HK1081451A1 (en) Medicinal composition
EP1594496A4 (en) Novel therapeutic method and compositions for topical administration
IL166062A0 (en) Compositions and methods for therapeutic treatment
GB0327050D0 (en) Therapeutic methods compositions and uses
ZA200603126B (en) Pharmaceutical compositions for therapeutic use
HK1062274A1 (en) Medicinal composition
AU2003235931A1 (en) Vintoperol-containing medicinal composition for transdermal administration

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050805

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20060321

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 17/00 20060101ALI20060315BHEP

Ipc: A61K 31/421 20060101AFI20060315BHEP

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20050805

Extension state: LT

Payment date: 20050805

17Q First examination report despatched

Effective date: 20061031

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090522